Related Experiment Video

Updated: Sep 16, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10

P H Langsjoen1, P H Langsjoen, K Folkers

  • 1Department of Medicine, Scott & White Clinic, Temple, TX.

International Journal of Tissue Reactions
|January 1, 1990
PubMed

Insights

Coenzyme Q10 supplementation significantly improved heart function and patient outcomes in chronic cardiomyopathy. This long-term study found CoQ10 safe and effective for managing heart conditions.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Chronic cardiomyopathy significantly impairs myocardial function and reduces quality of life.
  • Conventional therapies offer limited improvement for patients in advanced NYHA Classes III and IV.
  • Coenzyme Q10 (CoQ10) is a vital component of cellular energy production with potential cardioprotective effects.

Purpose of the Study:

  • To evaluate the long-term safety and efficacy of Coenzyme Q10 in patients with chronic cardiomyopathy.
  • To assess the impact of CoQ10 supplementation on blood CoQ10 levels, clinical status, and myocardial function.
  • To determine the effect of CoQ10 on survival rates in this patient population.

Main Methods:

  • An open-label, long-term study involving 143 patients with chronic stable cardiomyopathy (98% NYHA Classes III-IV).
  • Patients received 100 mg of oral Coenzyme Q10 daily, in addition to conventional medical treatment.
  • Comprehensive monitoring included blood CoQ10 levels, clinical status (NYHA Class), myocardial function (ejection fraction), and survival data over nearly 6 years.

Main Results:

  • Oral CoQ10 supplementation increased blood CoQ10 levels from 0.85 to 2.0 mcg/ml within 3 months, remaining stable thereafter.
  • Mean ejection fraction improved from 44% to 60% within 6 months, with 84% of patients showing significant improvement.
  • Eighty-five percent of patients experienced a one or two NYHA Class improvement, with encouraging survival rates (11.1% at 12 months, 17.8% at 24 months).

Conclusions:

  • Coenzyme Q10 is a safe and well-tolerated long-term therapy for chronic cardiomyopathy.
  • CoQ10 supplementation demonstrates significant efficacy in improving myocardial function and clinical status.
  • These findings support Coenzyme Q10 as an effective adjunctive treatment for patients with chronic heart conditions.

More Related Videos

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...